Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 9.34% since last year same period to $264.57Mn in the Q2 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 8.29% jump in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit fell -20.14% since last year same period to $26.67Mn in the Q2 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 40.44% jump in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin fell -26.96% since last year same period to 10.08% in the Q2 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 29.69% jump in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s price-to-earnings ratio after this Q2 2025 earnings stands at 19.14.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.13 - a -4.07% fall from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.13.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Acadia Pharmaceuticals Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.